CN106137539A - Hydrophilic polyurethane, hydrophilic polyurethane foam and wet wound dressing prepared from hydrophilic polyurethane foam - Google Patents
Hydrophilic polyurethane, hydrophilic polyurethane foam and wet wound dressing prepared from hydrophilic polyurethane foam Download PDFInfo
- Publication number
- CN106137539A CN106137539A CN201510540584.6A CN201510540584A CN106137539A CN 106137539 A CN106137539 A CN 106137539A CN 201510540584 A CN201510540584 A CN 201510540584A CN 106137539 A CN106137539 A CN 106137539A
- Authority
- CN
- China
- Prior art keywords
- hydrophilic polyurethane
- polyether polyol
- foaming
- wound dressing
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004814 polyurethane Substances 0.000 title claims abstract description 55
- 229920002635 polyurethane Polymers 0.000 title claims abstract description 55
- 229920005830 Polyurethane Foam Polymers 0.000 title abstract 4
- 239000011496 polyurethane foam Substances 0.000 title abstract 4
- 238000005187 foaming Methods 0.000 claims abstract description 27
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 18
- 229920000570 polyether Polymers 0.000 claims abstract description 18
- 229920005862 polyol Polymers 0.000 claims abstract description 18
- 150000003077 polyols Chemical class 0.000 claims abstract description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 17
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 17
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 17
- 239000005056 polyisocyanate Substances 0.000 claims abstract description 12
- 229920001228 polyisocyanate Polymers 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 239000002250 absorbent Substances 0.000 claims description 9
- 230000002745 absorbent Effects 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 4
- 229920000768 polyamine Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000004088 foaming agent Substances 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 48
- 206010052428 Wound Diseases 0.000 abstract description 46
- 230000029663 wound healing Effects 0.000 abstract description 11
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241000700145 Petromus typicus Species 0.000 description 11
- 206010072170 Skin wound Diseases 0.000 description 9
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- PAUHLEIGHAUFAK-UHFFFAOYSA-N 1-isocyanato-1-[(1-isocyanatocyclohexyl)methyl]cyclohexane Chemical compound C1CCCCC1(N=C=O)CC1(N=C=O)CCCCC1 PAUHLEIGHAUFAK-UHFFFAOYSA-N 0.000 description 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 description 2
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 239000012972 dimethylethanolamine Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical group OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- ADJMNWKZSCQHPS-UHFFFAOYSA-L zinc;6-methylheptanoate Chemical compound [Zn+2].CC(C)CCCCC([O-])=O.CC(C)CCCCC([O-])=O ADJMNWKZSCQHPS-UHFFFAOYSA-L 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- SPGMLBBQFVWTEL-UHFFFAOYSA-N methyl 5-hydroxy-2-methylpent-2-enoate Chemical group COC(=O)C(C)=CCCO SPGMLBBQFVWTEL-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- QATBRNFTOCXULG-UHFFFAOYSA-N n'-[2-(methylamino)ethyl]ethane-1,2-diamine Chemical compound CNCCNCCN QATBRNFTOCXULG-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01034—Non-adhesive bandages or dressings characterised by a property
- A61F13/01042—Absorbency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0223—Adhesive bandages or dressings with fluid retention members characterized by parametric properties of the fluid retention layer, e.g. absorbency, wicking capacity, liquid distribution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/4009—Two or more macromolecular compounds not provided for in one single group of groups C08G18/42 - C08G18/64
- C08G18/4081—Mixtures of compounds of group C08G18/64 with other macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/64—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63
- C08G18/6484—Polysaccharides and derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Materials For Medical Uses (AREA)
Abstract
A hydrophilic polyurethane is a star-block polyurethane obtained by reacting a first polyether polyol having at least three terminal hydroxyl groups with a polyisocyanate, followed by reaction with a second polyether polyol and hyaluronic acid. The invention also provides a hydrophilic polyurethane foam, which is obtained by foaming the hydrophilic polyurethane and the foaming component, and the holes are discontinuous closed holes. The invention also provides a wet wound dressing, which comprises a sheet-shaped absorption layer, wherein the material of the sheet-shaped absorption layer is the hydrophilic polyurethane or the hydrophilic polyurethane foam. The wet wound dressing of the invention has the hydrophilicity of keeping the wound moist and promoting the wound healing and effectively absorbing the wound exudate.
Description
Technical field
The present invention relates to a kind of polyurethane, particularly relate to a kind of hydrophilic polyurethane, hydrophilic polyurethane foaming body and prepared wet type wound dressing thereof.
Background technology
Due to the lifting of health care consciousness, the wound for surgical site infections looks after attention, accordingly, it is capable to avoid infection and protect the various wound dressing of wound to be in succession developed.
In order to promote wound healing further; would generally blending or the effective ingredient (such as: alginate, hyaluronic acid or its salt, secondary gallic acid bismuth etc.) of wound healing can be promoted in the coating of surface in dressing base material; but; blending or coating not only need extra processing technique; and these effective ingredient additionally added easily consume loss and need frequently more change dressings (about in 5 to 7 days); being likely to reduce the dressing assimilation effect for wound exudate because effective ingredient is absorbed by dressing base material, the help for wound healing is limited.
Summary of the invention
The first object of the present invention is to provide a kind of hydrophilic polyurethane, can be covered in wound as wound dressing, has holding wound moist concurrently and promote wound healing and can effectively absorb the hydrophilic of wound exudate.
The hydrophilic polyurethane of the present invention is to make the first polyether polyol react with polyisocyanates, then starlike (star) block (block) polyurethane obtained by reacting with the second polyether polyol and hyaluronic acid, this first polyether polyol contains at least three terminal hydroxyl.
The second object of the present invention is to provide a kind of hydrophilic polyurethane foaming body, and it is to make hydrophilic polyurethane as above and foaming component foaming obtain, and the hole of this hydrophilic polyurethane foaming body is the cap holes of discontinuous.
The third object of the present invention is to provide a kind of wet type wound dressing, comprises pieces of absorbent layer, and the material of this pieces of absorbent layer is hydrophilic polyurethane as above or hydrophilic polyurethane foaming body.
The beneficial effects of the present invention is: by star shaped block polyurethane obtained by polyether polyol, polyisocyanates and hyaluronic acid reaction, can prepare and can effectively facilitate wound healing and the wet type wound dressing of wound exudate can be absorbed.
Hereinafter will be described in detail with regard to present invention:
The star topology of this star shaped block polyurethane can make polyurethane have bigger specific surface area, is beneficial to promote the water absorption character of this hydrophilic polyurethane.
It is preferred that the weight average molecular weight scope of this hyaluronic acid is 500,000-2,500,000.The weight average molecular weight hyaluronic acid higher than 2,500,000 is less favorable for promoting wound healing.In a particular embodiment of the present invention, the weight average molecular weight of this hyaluronic acid is 1,000,000.
It is preferred that with the sum total of this first polyether polyol, this polyisocyanates, this second polyether polyol and this hyaluronic acid as 100mol%, the content range of this hyaluronic acid is 0.001-20mol%.More preferably, the content range of this hyaluronic acid is 0.001-10mol%.
It is preferred that this polyisocyanates is aliphatic polyisocyante, to avoid the risk of toxicity being likely to be of selected from aromatic compound.More preferably, this aliphatic polyisocyante is selected from 1, hexamethylene-diisocyanate (hexamethylene diisocyanate, HDI), methylene biscyclohexyl diisocyanate (methylene dicyclohexyl diisocyanate, H12MDI), different Buddhist ketone diisocyanate (isophorone diisocyanate, IPDI) or a combination thereof.In a particular embodiment of the present invention, this polyisocyanates is 1, hexamethylene-diisocyanate.
It is preferred that this first polyether polyol is poly-(propylene glycol) triol (PPG triol).
It is preferred that this second polyether polyol is Polyethylene Glycol (PEG).
In a particular embodiment of the present invention, this hydrophilic polyurethane be reacted with this polyisocyanates by poly-(propylene glycol) triol and extend into starlike prepolymer after, then carry out star shaped block polyurethane obtained by cross-linking reaction with Polyethylene Glycol and hyaluronic acid.
It is preferred that the weight average molecular weight scope of this Polyethylene Glycol is 1,000-6,000.If the weight average molecular weight of this Polyethylene Glycol is less than 1,000, bio-toxicity can be produced via metabolism；If the weight average molecular weight of this Polyethylene Glycol is more than 6,000, the operation of cross-linking reaction can be made to produce difficulty because viscosity is too high, if but add solvent and operate to reduce viscosity, then may cause dissolvent residual cytotoxic risk in dressing.
The hole of this hydrophilic polyurethane foaming body is the cap holes of discontinuous, to avoid cambium to grow into risk therein during wound healing, reduces the injury that may cause when removing.
It is preferred that this foaming component includes foaming agent, water, interfacial agent, polyamines and catalyst.This polyamines is the mechanical strength for increasing hydrophilic polyurethane, and more preferably, this polyamines is selected from 1,2-ethylenediamine, 1,4-butanediamine, 1,6-hexamethylene diamine, tetramine (triethylenetetramine, TETA) or polyetheramine (polyetheramine).This polyetheramine is selected from but is not limited to what Huntsman company producedThis catalyst is to react and produce carbon dioxide for being catalyzed polyisocyanates and the water of excess, more preferably, this catalyst can be selected from zinc Isoocatanoate, triethylenediamine (TEDA, DABCO), dimethyl cyclohexyl amine (DMCHA), dimethylethanolamine (DMEA), triethylamine (TEA), 1,8-diazabicylo [5.4.0] 11 carbon-7-alkene (DBU) or five methyl diethylentriamine (pentamethyldiethylenetriamine, PMDETA).
It is preferred that wet type wound dressing of the present invention also comprises backing, this pieces of absorbent layer is to be bonded on this backing, on the skin sticking in wound circumference.More preferably, in order to keep the stickiness of this backing, wet type wound dressing of the present invention also comprises release paper, is covered on this pieces of absorbent layer and this backing, for tearing before use.
Accompanying drawing explanation
Other the feature of the present invention and effect, will clearly present, wherein in reference to graphic embodiment:
Fig. 1 is schematic perspective view, and hydrophilic polyurethane or the hydrophilic polyurethane foaming body of the present invention are described；And
Fig. 2 is schematic perspective view, and the wet type wound dressing of the present invention is described.
Detailed description of the invention
Before the present invention is described in detail, it shall be noted that in the following description content, similar element is to be identically numbered to represent.
The present invention will be described further with regard to following example, however, it should be noted that such embodiment only illustrates use, and be not necessarily to be construed as the restriction that the present invention implements.
＜ embodiment 1 ＞ starlike hydrophilic polyurethane PU1
By 1mol PPG6000triol, (weight average molecular weight is 6,000) mix with 3mol HDI, after at 80 DEG C, reaction obtains starlike prepolymer in 1 hour, (weight average molecular weight is 1 to add 1mol PEG1000,000), (weight average molecular weight is 2 to 1.5mol PEG2000,000) and 0.5mol hyaluronic acid (weight average molecular weight is 1,000,000), at 80 DEG C, carry out cross-linking reaction 6 hours, obtain starlike hydrophilic polyurethane PU1.
＜ embodiment 2 ＞ starlike hydrophilic polyurethane PU2
0.5mol PPG6000triol and 2.5mol HDI is mixed, after at 80 DEG C, reaction obtains starlike prepolymer in 1 hour, (weight average molecular weight is 1 to add 0.85mol PEG1000,0.85mol PEG2000 and 0.1mol hyaluronic acid, 000,000), at 80 DEG C, carry out cross-linking reaction 6 hours, obtain starlike hydrophilic polyurethane PU2.
＜ application examples 1 ＞ wet type wound dressing DR1
Refering to Fig. 1, the starlike hydrophilic polyurethane PU1 of embodiment 1 is coated on mould release membrance after 1mol HDI mix and blend, heat 1 hour at 120 DEG C, obtain the pieces of absorbent layer 1 such as Fig. 1, be wet type wound dressing DR1.
＜ application examples 2 ＞ wet type wound dressing DR2
Refering to Fig. 1 and Fig. 2, by 0.1mol sodium bicarbonate (foaming agent), 0.4mol water, 0.5mol dimethione-polyoxyalkylene copolymers (interfacial agent), 0.1mol ethylenediamine and 0.1mol zinc Isoocatanoate (catalyst, purchased from the raw aurification Industries, Inc of TaiWan, China stannum, model is TMG620) it is mixed to get foaming component, then the starlike hydrophilic polyurethane PU2 of embodiment 2 is quickly stirred with this foaming component and mix, hydrophilic polyurethane foaming body is obtained after foaming and molding, and the hole of this hydrophilic polyurethane foaming body is the cap holes of discontinuous.This hydrophilic polyurethane foaming body is cut into appropriately sized pieces of absorbent layer 1, and its set is sticked on the backing 21 with stickiness, then by release paper 22, be covered on this pieces of absorbent layer 1 and this backing 21, the wet type wound dressing DR2 of the example that is applied 2.
＜ compares application examples 1 ＞ wound dressing CDR1
Relatively the wound dressing CDR1 of application examples 1 is general gauze.
＜ compares application examples 2 ＞ wound dressing CDR2 (sterilizing)
The relatively soft wound dressing 3662A that wound dressing CDR2 is 3M companies market of application examples 2, it is adhesive-bonded fabric with the material of Wound contact.
＜ compares application examples 3 ＞ wet type wound dressing CDR3 (sterilizing)
The relatively glue wound dressing that wet type wound dressing CDR3 is AMED companies market of application examples 3It is 2-hydroxyethyl methacrylic acid methyl ester (HEMA) with the material of Wound contact.
＜ wound healing test ＞
A. laboratory animal:
S.D. rat used in experiment is male Sprague-Dawley (S.D.) rat (8 weeks big, and body weight is about 200g) below.All of laboratory animal is raised in the Animal House of the Independent air conditioning that an illumination and dark are respectively 12 hours, room temperature maintains 22 DEG C and relative humidity maintains 42%, and moisture is supplied fully with feedstuff.On pretreatment, the period giving animal at least 2 week deacclimatizes environment.Feeding environment, process and all experimental arrangements about laboratory animal all meets experimental animal feeding management and the operating specification (Guide for the Care and Use of Laboratory Animals) of TaiWan, China NIH (National Institutes of Health, NIH).
B. the sterilizing (sterilization) of biological fiber dressing:
The application examples 1,2 above and wound dressing DR1, DR2 and CDR1 obtained by comparing in application examples 1 are given sterilizing with gamma ray (γ-ray) (dosage is as 40kGy), is then brought and carry out following experiment.
C. the formation of skin wound (skin wound):
The posterior components (dorsal part) of S.D. rat is carried out shaving (shaving), is then sterilized (disinfected) with iodine tincture (tincture of iodine) and 70% ethanol.Afterwards, scalpel (surgical knife) is used to cut out the skin wound with the size of about 2cm × 2cm and the degree of depth of about 2-3mm in the left side at the back of S.D. rat.
D. the using of dressing:
S.D. rat is randomly assigned to 2 experimental grouies and 3 matched groups (namely experimental group 1,2 and matched group 1-3) (often organizing n=3), and wherein the S.D. rat of each group is to form skin wound according to the method described in C item above.Then, the skin wound of the S.D. rat of experimental group 1 and 2 is applied respectively with sterilized wet type wound dressing DR1 and DR2 obtained by foundation B item above, and the skin wound of the S.D. rat of matched group 1,2 and 3 is applied with the sterilized wound dressing CDR1 obtained by foundation B item above respectively, compares the wound dressing CDR2 of application examples 2 and compare the wound dressing CDR3 of application examples 3.Experiment is lasted 7 days altogether, during after using dressing the 1st, 3,5 and 7 days, measures the wound area of each group of S.D. rat respectively, and result is as shown in table 1 below.
Table 1
It is appreciated that by upper table 1, after using dressing the 1st to 7 day, the area of the skin wound of the S.D. rat of experimental group 1 and 2 is all obviously reduced, wherein, the skin wound of the S.D. rat of experimental group 2 has been close to and has healed completely for the 7th day after using dressing, it is then the slowest that the area of the skin wound of the S.D. rat of matched group 1 to 3 reduces speed, and wet type wound dressing DR1 and DR2 of display experimental group 1 and 2 has the gauze compared with matched group 1-3 or the commercially available dressing significantly more help of wound dressing CDR1-CDR3 for wound healing.
In sum, hydrophilic polyurethane of the present invention and hydrophilic polyurethane foaming body are by star shaped block polyurethane obtained by polyether polyol, polyisocyanates and hyaluronic acid reaction, can prepare and can effectively facilitate wound healing and the wet type wound dressing of wound exudate can be absorbed, and the cap holes of hydrophilic polyurethane foaming body of the present invention is avoided that the injury that may cause when removing.Additionally, the raw material of wet type wound dressing of the present invention does not contains monomer or the cross-linking agent being likely to be of toxicity, the purpose of the present invention really can be reached.
The above, only embodiments of the invention, when not limiting, with this, the scope that the present invention implements, every simple equivalence made according to claims of the present invention and description changes and modifies, and the most still belongs to the scope of the present invention.
Claims (10)
1. a hydrophilic polyurethane, it is characterised in that: it is to make the first polyether polyol
React with polyisocyanates, then react with the second polyether polyol and hyaluronic acid obtained by
Star shaped block polyurethane, this first polyether polyol contains at least three terminal hydroxyl.
Hydrophilic polyurethane the most according to claim 1, it is characterised in that: this is transparent
The weight average molecular weight scope of matter acid is 500,000-2,500,000.
Hydrophilic polyurethane the most according to claim 1, it is characterised in that: with this
One polyether polyol, this polyisocyanates, this second polyether polyol and this hyaluronic acid
Sum total is 100mol%, and the content range of this hyaluronic acid is 0.001-20mol%.
Hydrophilic polyurethane the most according to claim 1, it is characterised in that: this polyisocyanate
Cyanate is aliphatic polyisocyante.
Hydrophilic polyurethane the most according to claim 1, it is characterised in that: this is first years old
Polyether polyol is poly-(propylene glycol) triol.
Hydrophilic polyurethane the most according to claim 1, it is characterised in that: this is second years old
Polyether polyol is Polyethylene Glycol.
Hydrophilic polyurethane the most according to claim 6, it is characterised in that: this poly-second
The weight average molecular weight scope of glycol is 1,000-6,000.
8. a hydrophilic polyurethane foaming body, it is characterised in that: it is to make according to right
Require that the hydrophilic polyurethane described in 1 and foaming component foaming obtain, and this hydrophilic polyurethane
The hole of foaming body is the cap holes of discontinuous.
Hydrophilic polyurethane foaming body the most according to claim 8, it is characterised in that:
This foaming component includes foaming agent, water, interfacial agent, polyamines and catalyst.
10. a wet type wound dressing, it is characterised in that: it comprises pieces of absorbent layer, should
The material of pieces of absorbent layer is hydrophilic polyurethane according to claim 1 or according to power
Profit requires the hydrophilic polyurethane foaming body described in 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104115023A TWI597075B (en) | 2015-05-12 | 2015-05-12 | Hydrophilic polyurethane, hydrophilic polyurethane foam and its preparation Wet wound dressing |
| TW104115023 | 2015-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106137539A true CN106137539A (en) | 2016-11-23 |
Family
ID=57348272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510540584.6A Pending CN106137539A (en) | 2015-05-12 | 2015-08-28 | Hydrophilic polyurethane, hydrophilic polyurethane foam and wet wound dressing prepared from hydrophilic polyurethane foam |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106137539A (en) |
| TW (1) | TWI597075B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106832206A (en) * | 2017-01-20 | 2017-06-13 | 中国科学院长春应用化学研究所 | A kind of medical dressing material with cooling capacity and preparation method thereof |
| CN108623772A (en) * | 2018-03-23 | 2018-10-09 | 凃懿庭 | A kind of preparation method of modified polyurethane hydrophilic material |
| CN109276749A (en) * | 2017-07-20 | 2019-01-29 | 泰陞国际科技股份有限公司 | Anti- adhesion dressing and its manufacturing method |
| CN109276739A (en) * | 2017-07-20 | 2019-01-29 | 泰陞国际科技股份有限公司 | Absorbent dressing and its manufacturing method |
| CN109276746A (en) * | 2017-07-20 | 2019-01-29 | 泰陞国际科技股份有限公司 | Except scar patch and its manufacturing method |
| CN113367891A (en) * | 2021-04-27 | 2021-09-10 | 苏州元禾医疗器械有限公司 | Multilayer dressing for assisting wound healing |
| CN113801285A (en) * | 2020-06-22 | 2021-12-17 | 昆山优瑞森医疗科技有限公司 | Preparation method of polyurethane foam dressing and wound dressing patch |
| CN114452434A (en) * | 2022-01-26 | 2022-05-10 | 武汉理工大学 | Broad-spectrum antibacterial polyurethane foam dressing and preparation method and application thereof |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3978855A (en) * | 1975-01-17 | 1976-09-07 | Ionics Lyo Products Company | Polyurethane foam surgical dressing |
| US5759570A (en) * | 1992-11-23 | 1998-06-02 | Johnson & Johnson Medical, Inc. | Multi-layer wound dressing |
| CN1389186A (en) * | 2002-07-30 | 2003-01-08 | 株式会社发裕瀑 | Multilayer polyporous foam dressing material and its producing method |
| CN1741824A (en) * | 2002-10-29 | 2006-03-01 | 株式会社Biopol | Polyurethane foam dressing for wound filler and method for man ufacturing thereof |
| US20080146983A1 (en) * | 2006-12-19 | 2008-06-19 | Biopol Co., Ltd. | Polyurethane foam dressing with improved moisturization |
| US20090177133A1 (en) * | 2008-01-04 | 2009-07-09 | Kristine Kieswetter | Reduced pressure dressing coated with biomolecules |
| CN101631571A (en) * | 2006-11-13 | 2010-01-20 | 奥苏尔公司 | Absorbent structure in an absorbent article |
| CN101730515A (en) * | 2007-06-21 | 2010-06-09 | 株式会社元比金 | Method for producing hydrophilic foam dressing and hydrophilic foam dressing produced thereby |
| CN102159165A (en) * | 2008-09-19 | 2011-08-17 | 拜尔材料科学股份公司 | Wound dressing with a polyurethane foam layer and a cover layer made of thermoplastic polymer |
| CN102223858A (en) * | 2008-10-02 | 2011-10-19 | L.R.R.&D.有限公司 | Interface layer wound dressing |
| CN103189026A (en) * | 2010-08-19 | 2013-07-03 | 保罗·哈特曼公司 | Use of a polyurethane foam as a wound dressing in negative pressure therapy |
| CN103889477A (en) * | 2011-11-11 | 2014-06-25 | 凯希特许有限公司 | Reduced-pressure, tunnel-wound dressings, system, and method |
| CN104244879A (en) * | 2012-04-20 | 2014-12-24 | 科洛普拉斯特公司 | An adhesive wafer |
| US20150080823A1 (en) * | 2012-05-29 | 2015-03-19 | 3M Innovative Properties Company | Absorbent article comprising polymeric foam and intermediates |
-
2015
- 2015-05-12 TW TW104115023A patent/TWI597075B/en active
- 2015-08-28 CN CN201510540584.6A patent/CN106137539A/en active Pending
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3978855A (en) * | 1975-01-17 | 1976-09-07 | Ionics Lyo Products Company | Polyurethane foam surgical dressing |
| US5759570A (en) * | 1992-11-23 | 1998-06-02 | Johnson & Johnson Medical, Inc. | Multi-layer wound dressing |
| CN1389186A (en) * | 2002-07-30 | 2003-01-08 | 株式会社发裕瀑 | Multilayer polyporous foam dressing material and its producing method |
| CN1741824A (en) * | 2002-10-29 | 2006-03-01 | 株式会社Biopol | Polyurethane foam dressing for wound filler and method for man ufacturing thereof |
| CN101631571A (en) * | 2006-11-13 | 2010-01-20 | 奥苏尔公司 | Absorbent structure in an absorbent article |
| US20080146983A1 (en) * | 2006-12-19 | 2008-06-19 | Biopol Co., Ltd. | Polyurethane foam dressing with improved moisturization |
| CN101730515A (en) * | 2007-06-21 | 2010-06-09 | 株式会社元比金 | Method for producing hydrophilic foam dressing and hydrophilic foam dressing produced thereby |
| US20090177133A1 (en) * | 2008-01-04 | 2009-07-09 | Kristine Kieswetter | Reduced pressure dressing coated with biomolecules |
| CN102159165A (en) * | 2008-09-19 | 2011-08-17 | 拜尔材料科学股份公司 | Wound dressing with a polyurethane foam layer and a cover layer made of thermoplastic polymer |
| CN102223858A (en) * | 2008-10-02 | 2011-10-19 | L.R.R.&D.有限公司 | Interface layer wound dressing |
| CN103189026A (en) * | 2010-08-19 | 2013-07-03 | 保罗·哈特曼公司 | Use of a polyurethane foam as a wound dressing in negative pressure therapy |
| CN103889477A (en) * | 2011-11-11 | 2014-06-25 | 凯希特许有限公司 | Reduced-pressure, tunnel-wound dressings, system, and method |
| CN104244879A (en) * | 2012-04-20 | 2014-12-24 | 科洛普拉斯特公司 | An adhesive wafer |
| US20150080823A1 (en) * | 2012-05-29 | 2015-03-19 | 3M Innovative Properties Company | Absorbent article comprising polymeric foam and intermediates |
Non-Patent Citations (2)
| Title |
|---|
| 朱洪法著: "《生活化学品与健康》", 30 April 2013, 北京金盾出版社 * |
| 程曾越著: "《通用树脂实用技术手册》", 30 November 1999, 北京中国石化出版社 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106832206A (en) * | 2017-01-20 | 2017-06-13 | 中国科学院长春应用化学研究所 | A kind of medical dressing material with cooling capacity and preparation method thereof |
| CN109276749A (en) * | 2017-07-20 | 2019-01-29 | 泰陞国际科技股份有限公司 | Anti- adhesion dressing and its manufacturing method |
| CN109276739A (en) * | 2017-07-20 | 2019-01-29 | 泰陞国际科技股份有限公司 | Absorbent dressing and its manufacturing method |
| CN109276746A (en) * | 2017-07-20 | 2019-01-29 | 泰陞国际科技股份有限公司 | Except scar patch and its manufacturing method |
| CN108623772A (en) * | 2018-03-23 | 2018-10-09 | 凃懿庭 | A kind of preparation method of modified polyurethane hydrophilic material |
| CN113801285A (en) * | 2020-06-22 | 2021-12-17 | 昆山优瑞森医疗科技有限公司 | Preparation method of polyurethane foam dressing and wound dressing patch |
| US11970569B2 (en) | 2020-06-22 | 2024-04-30 | Tronjen Medical Technology Inc. | Polyurethane foam sponge and wound dressing having the same |
| CN113367891A (en) * | 2021-04-27 | 2021-09-10 | 苏州元禾医疗器械有限公司 | Multilayer dressing for assisting wound healing |
| CN114452434A (en) * | 2022-01-26 | 2022-05-10 | 武汉理工大学 | Broad-spectrum antibacterial polyurethane foam dressing and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI597075B (en) | 2017-09-01 |
| TW201639600A (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106137539A (en) | Hydrophilic polyurethane, hydrophilic polyurethane foam and wet wound dressing prepared from hydrophilic polyurethane foam | |
| US5563233A (en) | Polyether polyurethane polymers and gels having improved absorption and slip properties | |
| US5932200A (en) | Polyether polyurethane polymers, gels, solutions and uses thereof | |
| US20060142685A1 (en) | Fluid wound dressing comprising partially cured polyurethane | |
| US6180132B1 (en) | Hydrogel wound dressing and the method of making and using the same | |
| CN101466412A (en) | Biomedical foam article | |
| CN109843380B (en) | Copolymer compositions for coating and adhesive applications | |
| US20160331860A1 (en) | Wet wound dressing | |
| TW200936625A (en) | Polyurethane foams for wound management | |
| Savelyev et al. | Preparation and characterization of new biologically active polyurethane foams | |
| BR112012023942B1 (en) | WOUND DRESSING AND PROCESS FOR THE PREPARATION OF A WOUND DRESSING | |
| CN112500772A (en) | Betaine cation waterborne polyurethane antibacterial coating and preparation method thereof | |
| JP2015501333A (en) | Alpha-alkoxysilane-terminated prepolymers for fast-curing spray foams with improved propellant gas solubility | |
| CN100522259C (en) | Medicated polyurethane foams | |
| CN109715692B (en) | Skin contact adhesives and methods of making and using the same | |
| TW202103737A (en) | Water glue for scar film and its preparation method including a hydrophobic polyol preparing step, a hydrophilic diisocyanate preparing step, a first prepolymer obtaining step, a first prepolymer crosslinking step, and a second prepolymer endcapping step | |
| CN102971353A (en) | Method for producing hydrophilic, aliphatic polyurethane foams having low bulk density | |
| CN111748071A (en) | Hydrophilic polyurethane foam dressing and preparation method thereof | |
| CN106310497A (en) | Negative pressure therapeutic apparatus | |
| TWM513030U (en) | Wet wound dressing | |
| US9511147B2 (en) | Interpolymer network delivery system | |
| RU2597902C1 (en) | Polymer adhesive | |
| TWI597080B (en) | Negative pressure treatment device | |
| US20140234283A1 (en) | Fast-curing alkoxysilane spray foams | |
| KR100846141B1 (en) | Composition of polyurethane hydrogel for medical use and continuous film forming method of the polyurethane hydrogel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161123 |